
ACAN is the stock symbol for Acan Therapeutics, a biopharmaceutical company focused on developing treatments for rare and serious diseases.
Acan Therapeutics is a clinical-stage company, meaning it's currently testing its treatments in human clinical trials.
The company's lead product candidate is AC-100, a treatment for a rare genetic disorder that affects the body's ability to break down certain proteins.
AC-100 has shown promising results in early clinical trials, with significant improvements in patient outcomes.
Additional reading: Sentinel One Stock Symbol
If this caught your attention, see: Znga Stock Symbol
Company Overview
ACAN is a company that operates in the industry of cannabis cultivation.
ACAN has a significant presence in the United States, with cultivation facilities located in California and Oregon.
The company focuses on producing high-quality cannabis products for both medical and recreational use.
About the Company
AmeriCann, Inc. was founded in 2010.
The company operates in the cannabis industry, specifically designing, developing, leasing, and operating cannabis cultivation, processing, and manufacturing facilities in the United States.
AmeriCann's flagship project is the Massachusetts Cannabis Center, located on a 52.6-acre parcel of undeveloped land in Freetown, Massachusetts.
The company provides both medical cannabis and adult-use cannabis.
Here's a quick rundown of AmeriCann's leadership:
AmeriCann has a small team, with only 3 employees as of the time of our records.
Press Release: AmeriCann, Inc
AmeriCann, Inc. has a history of releasing annual reports, with the most recent one being the Annual Report for Fiscal Year Ending 09 30, 2024 (Form 10 K) on January 15th.
The company has also filed a Late Filing Notice (Form NT 10-K) on December 27th, indicating a delay in submitting their annual report.
AmeriCann has made several material agreements, with the first one filed on November 23, 2011, and another one filed on December 13, 2022.
The company has also terminated a material agreement, which was filed on July 24, 2007.
Here are the key dates for AmeriCann's press releases:
Stock Performance
Stock Performance for AmeriCann (ACAN) has been quite volatile. The current share price is a mere $0.041.
Over the past 52 weeks, the stock has hit a high of $0.10 and a low of $0.015. The beta of ACAN is 1.16, indicating a relatively high level of volatility.
The 1-month change is a significant 36.48%, while the 3-month change is an even more impressive 108.28%. However, if you look at the 1-year change, you'll see that it's actually a decline of 31.67%.
Here's a quick summary of the stock's performance over different time periods:
These numbers give you a sense of the stock's overall performance and its potential risks.
Competitors and Market
ACAN's main competitors in the cannabis industry are companies like Canopy Growth and Aurora Cannabis, which have a significant market share and strong brand recognition.
ACAN's focus on high-quality, small-batch cannabis products allows it to differentiate itself from larger competitors.
ACAN has a strong presence in the US market, with a significant number of dispensaries carrying its products.
The US market for cannabis products is expected to grow significantly in the next few years, driven by changing laws and regulations.
ACAN is well-positioned to take advantage of this growth, with a strong brand and a wide range of products.
ACAN's products are priced competitively with other premium cannabis brands, making them an attractive option for customers.
ACAN's focus on quality and customer service has helped it build a loyal customer base.
Worth a look: Us Stock Marke
Featured Images: pexels.com


